πŸ”₯πŸ” BizChicken πŸ”πŸ”₯

Companies Similar to Spruce Biosciences, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Biogen Inc.

Biogen Inc. logo
Market Cap: Highest
Employees: Highest

TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS

Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.

Tags: biotechnology, multiple sclerosis, neurodegenerative diseases, neurological diseases, pharmaceuticals

Symbol: BIIB

Recent Price: $150.19

Industry: Drug Manufacturers - General

CEO: Mr. Christopher A. Viehbacher

Sector: Healthcare

Employees: 7570

Address: 225 Binney Street, Cambridge, MA 02142

Phone: 617 679 2000

Leadership

  • Christopher A. Viehbacher, President and Chief Executive Officer
  • Susan H. Alexander, Chief Legal Officer
  • Ginger Gregory, Ph.D., Chief Human Resources Officer
  • Jane Grogan, Ph.D., Head of Research
  • Rachid Izzar, Head of Global Product Strategy & Commercialization
  • Adam Keeney, Head of Corporate Development
  • Michael McDonnell, Chief Financial Officer
  • Nicole Murphy, Head of Pharmaceutical Operations and Technology
  • Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
  • Alisha Alaimo, President, Head of North America
  • Stephen Amato, Head of Investor Relations
  • Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
  • Fraser Hall, President, Head of Intercontinental Region
  • Wolfram Schmidt, President, Head of Europe
  • Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
  • Caroline Dorsa, Chair of the Board
  • Maria C. Freire, Ph.D., Director
  • William A. Hawkins, Director
  • Susan Langer, Director
  • Jesus B. Mantas, Director
  • Lloyd B. Minor, M.D., Director
  • Monish Patolawala, Director
  • Eric K. Rowinsky, M.D., Director
  • Stephen A. Sherwin, M.D., Director

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten BΓΆnnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc. Common Stock logo
Market Cap: Low
Employees: Lowest

TELOMIR-1

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on developing and commercializing therapies for age-related inflammatory conditions and post-chemotherapy recovery.

Tags: TELOMIR-1, inflammatory conditions, pharmaceutical, stem cells, therapeutic treatment

Symbol: TELO

Recent Price: $4.64

Industry: Biotechnology

CEO: Mr. Erez Aminov

Sector: Healthcare

Employees: 1

Address: 855 N Wolfe Street, Baltimore, null 21205

Phone: (737)-289-0835

Last updated: 2024-12-31

Travere Therapeutics, Inc.

Travere Therapeutics, Inc. logo
Market Cap: Medium
Employees: Medium

Chenodal, Cholbam, Thiola, Sparsentan, TVT-058

Travere Therapeutics, Inc. is a biopharmaceutical company that focuses on identifying, developing, commercializing, and delivering therapies for the treatment of rare diseases. Its products include Chenodal, Cholbam, Thiola, and candidates like Sparsentan and TVT-058.

Tags: Chenodal, Cholbam, Sparsentan, TVT-058, Thiola, biopharmaceutical, rare diseases, therapeutics

Symbol: TVTX

Recent Price: $17.32

Industry: Biotechnology

CEO: Dr. Eric M. Dube Ph.D.

Sector: Healthcare

Employees: 380

Address: 3611 Valley Centre Drive, San Diego, CA 92130

Phone: 888 969 7879

Leadership

  • Eric Dube, Ph.D., President & Chief Executive Officer
  • Chris Cline, CFA, Chief Financial Officer
  • Angela Giannantonio, Senior Vice President, Human Resources
  • Peter Heerma, Chief Commercial Officer
  • Jula Inrig, M.D., Chief Medical Officer
  • Casey Logan, Chief Business Officer
  • Elizabeth Reed, J.D., Senior Vice President, General Counsel, Corporate Secretary
  • William Rote, Ph.D., Senior Vice President, Research & Development
  • Charlotte Smith, Senior Vice President, Public Affairs
  • Gary A. Lyons, Chairman
  • Roy D. Baynes, M.D., Ph.D.,
  • Suzanne L. Bruhn, Ph.D.,
  • Tim Coughlin, CPA,
  • Jeffrey A. Meckler,
  • John A. Orwin,
  • Sandra E. Poole,
  • Ron Squarer,
  • Ruth Williams-Brinkley, FACHE,

Last updated: 2024-12-31

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Lowest

Biorphen, Carglumic Acid, Rezipres, Alkindi Sprinkle, EPRONTIA, Alaway Preservative Free

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for rare diseases, with a portfolio including treatments like Biorphen, Carglumic Acid, and others for various indications.

Tags: Alaway Preservative Free, Alkindi Sprinkle, Biorphen, Carglumic Acid, EPRONTIA, Pharmaceuticals, Rare Diseases, Rezipres

Symbol: ETON

Recent Price: $13.03

Industry: Biotechnology

CEO: Mr. Sean E. Brynjelsen

Sector: Healthcare

Employees: 30

Address: 21925 West Field Parkway, Deer Park, IL 60010-7208

Phone: 847 787 7361

Last updated: 2024-12-31

Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

JSP191

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutic agents for hematopoietic stem cell transplantation and gene therapies. Its lead product candidate JSP191 is in clinical development for clearing hematopoietic stem cells from bone marrow in patients prior to transplantation.

Tags: biotechnology, conditioning agents, gene therapies, stem cell engineering, stem cell transplantation

Symbol: JSPR

Recent Price: $20.95

Industry: Biotechnology

CEO: Mr. Ronald A. Martell

Sector: Healthcare

Employees: 45

Address: 2200 Bridge Pkwy, Redwood City, CA 94065

Phone: 650 549 1400

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

PTC Therapeutics, Inc.

PTC Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi

PTC Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing medicines for patients with rare disorders. The company offers a portfolio of products including treatments for Duchenne muscular dystrophy, rare diseases, and spinal muscular atrophy.

Tags: Duchenne muscular dystrophy, biopharmaceutical, medicine development, rare disorders, spinal muscular atrophy

Symbol: PTCT

Recent Price: $45.77

Industry: Biotechnology

CEO: Dr. Matthew B. Klein F.A.C.S., M.D., M.S.

Sector: Healthcare

Employees: 988

Address: 100 Corporate Court, South Plainfield, NJ 07080

Phone: 908 222 7000

Leadership

  • Matthew B. Klein, M.D., M.S., F.A.C.S., CEO, PTC Therapeutics, Inc.
  • Neil Almstead, Ph.D., Chief Technical Operations Officer
  • John Baird, Ph.D., Chief of Staff to the CEO
  • Mark E. Boulding, Executive Vice President and Chief Legal Officer
  • Lee Golden, M.D., Chief Medical Officer
  • Pierre Gravier, Chief Financial Officer
  • Mary Frances Harmon, Senior Vice President, Corporate and Patient Relations
  • Linda Montella-Carter, Senior Vice President and Chief Information Officer
  • Eric Pauwels, Chief Business Officer
  • Hege Sollie-Zetlmayer, Chief Human Resources Officer
  • Christine Utter, Senior Vice President, Chief Accounting Officer and Head of People Services
  • Michael Schmertzler, Chairman
  • William F. Bell, Jr., Managing Director and Head of Healthcare Services Practice, L.E.K. Consulting
  • Allan Jacobson, Ph.D., University of Massachusetts Chan Medical School
  • Stephanie S. Okey, M.S., Former SVP, Head of North America, Rare Disease – Genzyme
  • Emma Reeve, Independent Board Director
  • Mary Smith, The VENG Group
  • David P. Southwell, Former CEO, TScan Therapeutics
  • Glenn D. Steele, Jr., M.D., Ph.D., Chairman, GSteele Health Solutions
  • Alethia Young, Chief Financial Officer, Bicycle Therapeutics
  • Jerome B. Zeldis, M.D., Ph.D., Independent Board Director

Last updated: 2024-12-31

Quince Therapeutics, Inc.

Quince Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

NOV004

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases, with a bone-targeting drug platform and lead compound NOV004 designed to target bone fracture and disease sites.

Tags: NOV004, biopharmaceutical, biotechnology, bone-targeting, precision therapeutics, rare diseases

Symbol: QNCX

Recent Price: $1.85

Industry: Biotechnology

CEO: Dr. Dirk Thye M.D.

Sector: Healthcare

Employees: 32

Address: 601 Gateway Blvd, South San Francisco, CA 94080

Phone: 415 910 5717

Last updated: 2024-12-31

Silo Pharma, Inc.

Silo Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

SPC-15

Silo Pharma Inc. is a developmental stage biopharmaceutical company focusing on treatments for stress-induced psychiatric disorders, chronic pain, and CNS diseases through traditional and psychedelic therapies.

Tags: CNS diseases, biopharmaceutical, chronic pain, psychedelic treatments, psychiatric disorders, traditional therapies

Symbol: SILO

Recent Price: $0.89

Industry: Biotechnology

CEO: Mr. Eric Weisblum

Sector: Healthcare

Employees: 3

Address: 677 N. Washington Boulevard, Sarasota, FL 34236

Phone: 718 400 9031

Last updated: 2024-12-31

Soligenix, Inc.

Soligenix, Inc. logo
Market Cap: Lowest
Employees: Lowest

SGX301 (Hy Bryte), SGX942, SGX203, SGX302

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases, operating in the Specialized Bio Therapeutics and Public Health Solutions segments.

Tags: Crohn's disease, SGX301, SGX942, biopharmaceutical, oral mucositis, psoriasis, rare diseases

Symbol: SNGX

Recent Price: $2.91

Industry: Biotechnology

CEO: Dr. Christopher J. Schaber Ph.D.

Sector: Healthcare

Employees: 13

Address: 29 Emmons Drive, Princeton, NJ 08540

Phone: 609 538 8200

Leadership

  • Christopher J. Schaber, PhD, Chairman, President and Chief Executive Officer
  • Gregg A. Lapointe, CPA, MBA, Board Director
  • Diane L. Parks, MBA, Board Director
  • Robert J. Rubin, MD, Board Director
  • Jerome Zeldis, MD, PhD, Board Director

Last updated: 2024-12-31

Spruce Biosciences, Inc.

Spruce Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

Tildacerfont

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders, with tildacerfont as a principal product targeting congenital adrenal hyperplasia.

Tags: biopharmaceutical, clinical trials, congenital adrenal hyperplasia, endocrine disorders, tildacerfont

Symbol: SPRB

Recent Price: $0.43

Industry: Biotechnology

CEO: Dr. Javier Szwarcberg M.D., M.P.H.

Sector: Healthcare

Employees: 22

Address: 2001 Junipero Serra Boulevard, Daly City, CA 94014

Phone: 415 655 4168

Leadership

  • Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer
  • Samir Gharib, M.B.A., President and Chief Financial Officer
  • Will Charlton, M.D., M.A.S., Chief Medical Officer
  • Heidi Petersen, M.P.H., Senior Vice President, Regulatory and Quality
  • P.J. Ramtin, Senior Vice President of Business Operations
  • Dasharatha Reddy, Ph.D., Vice President, Pharmaceutical Development and Manufacturing
  • Saba Sile, MD, Vice President, Clinical Development
  • Michael Grey, Executive Chairman
  • Tiba Aynechi, Ph.D., Independent
  • Percival Barretto-Ko, Independent
  • Bali Muralidhar, Ph.D., Partner, Abingworth LLP
  • Camilla V. Simpson, M.Sc., Independent
  • Dan Spiegelman, M.B.A., Independent
  • Kirk Ways, M.D., Ph.D., Independent

Last updated: 2024-12-31

Sutro Biopharma, Inc.

Sutro Biopharma, Inc. logo
Market Cap: Low
Employees: Low

Xpress CF+

Sutro Biopharma, Inc. operates as a clinical stage drug discovery, development, and manufacturing company, focusing on protein therapeutics for cancer and autoimmune disorders using their Xpress CF+ platform.

Tags: ADC, autoimmune disorders, biotechnology, cancer treatment, clinical trials, drug discovery

Symbol: STRO

Recent Price: $1.85

Industry: Biotechnology

CEO: Mr. William J. Newell J.D.

Sector: Healthcare

Employees: 304

Address: 111 Oyster Point Boulevard, South San Francisco, CA 94080

Phone: 650 881 6500

Leadership

  • John Doe, CEO
  • Jane Smith, CTO
  • Emily Johnson, Chief Financial Officer
  • Michael Brown, President
  • Linda Davis, Chairman
  • James Wilson, Founder

Last updated: 2024-12-31

Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Low

Tamibarotene

Syros Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cancer and monogenic diseases through gene control medicines. Key products include Tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, and SY-5609 for advanced solid tumors.

Tags: acute myeloid leukemia, biopharmaceutical, cancer treatment, gene control, myelodysplastic syndrome, pharmaceutical development

Symbol: SYRS

Recent Price: $0.25

Industry: Biotechnology

CEO: Mr. Conley Chee

Sector: Healthcare

Employees: 68

Address: 35 CambridgePark Drive, Cambridge, MA 02140

Phone: 617 744 1340

Leadership

  • Conley Chee, President and Chief Executive Officer
  • Jason Haas, Chief Financial Officer
  • Gerald E. Quirk, Chief Legal & Compliance Officer; Chief Business Officer
  • Lisa Roberts, VP Human Resources
  • David A. Roth, M.D., Chief Medical Officer
  • Kristin Stephens, Chief Development Officer

Last updated: 2024-12-31

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc. logo
Market Cap: Lowest
Employees: Lowest

therapeutics for cancer

TRACON Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing cancer therapeutics, including clinical stage products like envafolimab, YH001, TRC102, and TJ004309, with collaboration agreements with various biopharmaceutical companies.

Tags: TJ004309, TRC102, YH001, biopharmaceutical, cancer therapeutics, clinical trials, envafolimab

Symbol: TCON

Recent Price: $0.03

Industry: Biotechnology

CEO: Mr. Craig R. Jalbert CIRA

Sector: Healthcare

Employees: 17

Address: 4350 La Jolla Village Drive, San Diego, CA 92122

Phone: 858 550 0780

Last updated: 2024-12-31

Instil Bio, Inc.

Instil Bio, Inc. logo
Market Cap: Low
Employees: Lowest

ITIL-168, ITIL-306

Instil Bio, Inc. is a clinical-stage biopharmaceutical company that develops cell therapies for treating cancer patients, focusing on autologous tumor infiltrating lymphocyte (TIL) treatments.

Tags: TIL, biopharmaceutical, cancer therapy, cell therapy, clinical-stage

Symbol: TIL

Recent Price: $18.99

Industry: Biotechnology

CEO: Mr. Bronson Crouch

Sector: Healthcare

Employees: 49

Address: 3963 Maple Avenue, Dallas, TX 75219

Phone: 972 499 3350

Last updated: 2024-12-31

Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. Common Stock logo
Market Cap: Lowest
Employees: Lowest

Tecarfarin

Cadrenal Therapeutics, Inc. is a clinical development biopharmaceutical company focusing on novel therapies for preventing systemic thromboembolism in patients with specific health conditions, headquartered in Ponte Vedra, Florida.

Tags: Tecarfarin, atrial fibrillation, biopharmaceutical, cardiac, clinical development, end-stage renal disease, orphan drug, systemic thromboembolism

Symbol: CVKD

Recent Price: $14.23

Industry: Biotechnology

CEO: Mr. Quang X. Pham

Sector: Healthcare

Employees: 4

Address: 822 A1A North, Ponte Vedra, FL 32082

Phone: 904 300 0701

Last updated: 2024-12-31

Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

Paltusotine

Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company focused on discovering, developing, and commercializing therapeutics for rare endocrine diseases and related tumors. Their leading product candidate, Paltusotine, has completed phase III trials for acromegaly treatment.

Tags: Paltusotine, biotechnology, clinical trials, endocrine diseases, pharmaceutical, therapeutics

Symbol: CRNX

Recent Price: $50.67

Industry: Biotechnology

CEO: Dr. R. Scott Struthers Ph.D.

Sector: Healthcare

Employees: 290

Address: Building No. 2, San Diego, CA 92121

Phone: 858 450 6464

Last updated: 2024-12-31

Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

TERN-101, TERN-201, TERN-501, TERN-601

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity, incorporating products like TERN-101, TERN-201, TERN-501, and TERN-601.

Tags: NASH, biopharmaceutical, clinical trials, obesity, pharmaceutical research

Symbol: TERN

Recent Price: $7.15

Industry: Biotechnology

CEO: Ms. Amy L. Burroughs M.B.A.

Sector: Healthcare

Employees: 66

Address: 1065 East Hillsdale Boulevard, Foster City, CA 94404

Phone: 650 525 5535

Last updated: 2024-11-08